Oncaspar and Bradycardia - a phase IV clinical study of FDA data

Summary:

Bradycardia is reported as a side effect among people who take Oncaspar (pegaspargase), especially for people who are male, 2-9 old, have been taking the drug for < 1 month also take Methotrexate, and have Acute lymphocytic leukemia (all).

The phase IV clinical study analyzes which people have Bradycardia when taking Oncaspar. It is created by eHealthMe based on reports of 5,503 people who have side effects when taking Oncaspar from the FDA, and is updated regularly.

What is Oncaspar?

Oncaspar has active ingredients of pegaspargase. eHealthMe is studying from 5,504 Oncaspar users. Check the latest studies of Oncaspar.

What is Bradycardia?

Bradycardia (abnormally slow heart action) is found to be associated with 1,930 drugs and 3,118 conditions by eHealthMe. Check the latest studies of Bradycardia.

On Jul, 10, 2026

5,503 people reported to have side effects when taking Oncaspar.
Among them, 77 people (1.4%) have Bradycardia.

Among these 77 people:

How long have people been on Oncaspar when they have Bradycardia? *

What is the gender of people who have Bradycardia when taking Oncaspar? *

female: 35.71 %
male: 64.29 %

What is the age of people who have Bradycardia when taking Oncaspar? *

What are other drugs people take besides Oncaspar? *

What are other side effects people have besides Bradycardia? *

Hypotension (abnormally low blood pressure): 44 people, 57.14%
Ascites (accumulation of fluid in the abdominal cavity): 19 people, 24.68%
Abdominal Pain: 18 people, 23.38%
Respiratory Distress (difficulty in breathing): 16 people, 20.78%
Nausea And Vomiting: 15 people, 19.48%
Febrile Neutropenia (fever with reduced white blood cells): 15 people, 19.48%
Arrhythmias (irregular heartbeat): 15 people, 19.48%
Septic Shock (shock due to blood infection): 14 people, 18.18%
Cardiac Arrest: 13 people, 16.88%
Fever: 12 people, 15.58%

What are the existing conditions these people have? *

Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 15 people, 19.48%
High Blood Pressure: 7 people, 9.09%
Cardiac Disorder: 7 people, 9.09%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 1 person, 1.30%
Peripheral Sensory Neuropathy (damage to one or more of your peripheral nerves): 1 person, 1.30%
Klebsiella Infection: 1 person, 1.30%
Burning Sensation: 1 person, 1.30%

* Approximation only. Some reports may have incomplete information.

Do you take Oncaspar and have Bradycardia?

- Check whether Bradycardia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Oncaspar:

Oncaspar (5,504 reports)

Bradycardia treatments and more:

Bradycardia (61,180 reports)

Browse all side effects of Oncaspar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bradycardia:

Bradycardia (1,930 drugs)

Browse all the conditions that are associated with Bradycardia:

Bradycardia (3,118 conditions)

Related publications that referenced our studies

Schlumbrecht MP, Hehr K, "Cisplatin-induced bradycardia and the importance of the QT interval", Journal of Oncology Pharmacy Practice, 2015 Jan .
Oflaz MB, Kucukdurmaz Z, Guven AS, Karapinar H, Kaya A, Sancakdar E, Deveci K, Gul I, Erdem A, Cevit O, Icagasioglu FD, "Bradycardia seen in children with Crimean-Congo hemorrhagic fever", Vector-Borne and Zoonotic Diseases, 2013 Nov .
Schlumbrecht MP, Hehr K, "Cisplatin-induced bradycardia and the importance of the QT interval", Journal of Oncology Pharmacy Practice, 2015 Jan .
Oflaz MB, Kucukdurmaz Z, Guven AS, Karapinar H, Kaya A, Sancakdar E, Deveci K, Gul I, Erdem A, Cevit O, Icagasioglu FD, "Bradycardia seen in children with Crimean-Congo hemorrhagic fever", Vector-Borne and Zoonotic Diseases, 2013 Nov .

How the study uses the data?

The study uses data from the FDA. It is based on pegaspargase (the active ingredients of Oncaspar) and Oncaspar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.